Printer Friendly

Biologic Activity of LLL12 against Canine Osteosarcoma

Osteosarcoma (OSA) is the most common primary bone tumor in dogs and it accounts for about 85 percent of all bone tumors. More than 10,000 new canine cases are diagnosed each year. It often affects Rottweilers, greyhounds, Scottish deerhounds and golden retrievers. Traditional treatment-which hasn't substantially improved in the last 15 years-involves removal of the tumor, usually through limb amputation, followed by chemotherapy. Despite this aggressive treatment, the majority of patients don't survive longer than two years after treatment because the tumor spreads (metastasizes) to the dog's lungs. Researchers at the Ohio State University have shown that STAT3, a protein important in a tumor cell's ability to metastasize and resist chemotherapy, is essential for cancer cell survival. In this project researchers are evaluating a STAT3 inhibiting compound for its ability to kill OSA tumor cells with potentially fewer side effects than traditional chemotherapy. Compounds that target STAT3 represent cutting-edge research that could improve our ability to treat OSA in the future.

D09CA-500
Dr. Cheryl London, The Ohio State University